

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 and mental disorders, learning disability, increased virulence of variants

Peer reviewed journals featured:

- A systematic review on mental disorders and the risk of COVID-19-related mortality, hospitalisation, and ICU admission [here](#)
- Observational studies on:
 - The risk of COVID-19 hospital admission and death for people with a learning disability [here](#) and associated editorial [here](#)
 - Use of a paediatric headbox as an aerosol and droplet barrier [here](#)
 - Association of remdesivir treatment with survival and hospital length of stay among US veterans [here](#) and associated commentary [here](#)
 - SARS-CoV-2 testing and sequencing for international arrivals in the UK [here](#)
 - Characteristics and outcomes of COVID-19 patients living with and without obesity in the US, Spain, and the UK [here](#)
- Modelling studies on:
 - The impact of vaccination to control COVID-19 burden in the US [here](#)
 - Predictability of COVID-19-related morbidity and mortality to establish proactive protocols of countermeasures [here](#)
- Editorials on:
 - Defining COVID-19 elimination and eradication [here](#)
 - Caution, vaccines, testing [here](#)
- Commentary on:
 - Potential benefits of expanded COVID-19 surveillance in the US [here](#)
 - SARS-CoV-2 vaccination in immunosuppressed interstitial lung disease patients [here](#)
 - Averting future vaccine injustice [here](#)

Letters and correspondence discussed:

- Long-term symptoms after SARS-CoV-2 infection in children and adolescents [here](#)
- Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19 [here](#)

Pre-peer review articles featured:

- Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada [here](#)
- The infection fatality rate of COVID-19 in community-dwelling populations [here](#)
- Appropriate relaxation of non-pharmaceutical interventions to minimise the risk of a resurgence in SARS-CoV-2 infections [here](#)
- SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralisation in sera from Sinovac recipients and COVID-19 patients [here](#)
- The health impacts of a 4-month long community-wide COVID-19 lockdown in Victoria [here](#)

Guidance and reports

- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The Australian Technical Advisory Group Immunisation (ATAGI) released its weekly update [here](#)

News and blogs

- Vaccine centres operating at 30% capacity as young people stay away in England [here](#)
- RSV, flu, and COVID-19 could push NHS to breaking point in England [here](#)
- Enforced restrictions to care home access in the UK [here](#)
- Emergency use authorisation of COVID-19 vaccines in children is appropriate and necessary [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), and [surgery and COVID-19](#).